Phaseline

Companies › HB BioTech

HB BioTech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HB-1
Angiotensin II receptor antagonist (telmisartan) and calcium channel blocker (verapamil)
AGTR1, Ion channelsPhase 2PTSDSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07499440HB-1Phase 2PTSDPsychiatrySep 2027

Targets

AGTR1 (1) Ion channels (1)

Companies with the same targets

Xenon Pharmaceuticals Praxis Precision Medicines THPharm Chong Kun Dang Pharmaceutical Yuhan Shenzhen Salubris Pharmaceuticals Travere Therapeutics Shin Poong Pharmaceutical Chia Tai Tianqing Pharmaceutical Group Encoded Therapeutics

Companies built like this

Newron Pharmaceuticals Draig Therapeutics Kadence Bio Beckley Psytech Synendos Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.